Malarone

Atovaquone/proguanil, the active ingredient in Malarone, is an antiprotozoal presented as a 250 mg atovaquone / 100 mg proguanil oral tablet for oral use. It treats and prevents malaria infection in travelers and residents of endemic areas.

GNH USA supplies Malarone as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Malarone is an antiprotozoal used in malaria prevention and treatment. - Prevention of malaria infection: provides prophylactic protection for travelers and residents in endemic regions. - Treatment of acute uncomplicated malaria caused by Plasmodium species: clears parasitemia and resolves clinical symptoms. - Chemoprophylaxis for chloroquine‑resistant malaria: offers an alternative regimen where other prophylactics are ineffective.

Malarone may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient cranial discomfort. - Abdominal pain: cramp-like discomfort in the abdomen. - Vomiting: occasional expulsion of stomach contents.

Serious or Rare Side Effects: - Severe skin reactions: including Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic enzyme elevation: potential liver function abnormalities. - Hemolytic anemia in G6PD deficiency: breakdown of red blood cells. - Anaphylaxis: life‑threatening allergic response.

Before prescribing Malarone, consider the following precautions to ensure safe use. - Pregnancy: safety not established; use only if potential benefit justifies the risk. - Breastfeeding: unknown effects on the infant; weigh risks versus benefits. - Renal impairment: dose adjustment may be required in severe kidney dysfunction. - Hepatic impairment: use with caution in patients with liver disease. - Drug resistance: ensure adherence to the full regimen to prevent resistance development. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Malarone can interact with several medicines; awareness of major and moderate interactions helps manage therapy.

Major Interactions (Avoid): - Rifampin: markedly reduces atovaquone plasma concentrations, compromising efficacy. - Cimetidine: may increase atovaquone levels, raising risk of toxicity. - Protease inhibitors (e.g., ritonavir): can alter metabolism of both components.

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: decrease atovaquone absorption; separate dosing by at least 2 hours. - Warfarin: potential alteration of INR; monitor coagulation parameters. - Statins (e.g., simvastatin): increased risk of myopathy; observe for muscle symptoms.